StockData
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.07−0.32 (-0.93%)

Close on Nov 18, 2026Market cap $2.25BP/E 6.3Yield –

Lakefront Biotherapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was €1.11B, up 303.5% from the year before. Over ten years it grew 39.6% a year on average. The highest annual figure on record is €1.11B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025€1.11B+303.5%
FY2024Dec 31, 2024€275.65M+15.0%
FY2023Dec 31, 2023€239.72M-0.6%
FY2022Dec 31, 2022€241.25M+2.9%
FY2021Dec 31, 2021€234.38M-51.0%
FY2020Dec 31, 2020€478.05M-42.7%
FY2019Dec 31, 2019€834.90M+199.6%
FY2018Dec 31, 2018€278.67M+119.3%
FY2017Dec 31, 2017€127.09M-1.9%
FY2016Dec 31, 2016€129.52M+227.4%
FY2015Dec 31, 2015€39.56M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2021Jun 30, 2021€139.77M+419.0%
Q2 FY2020Jun 30, 2020€99.59M–
Q2 FY2019Jun 30, 2019€58.74M–
Q2 FY2018Jun 30, 2018€49.68M–
Q2 FY2017Jun 30, 2017€26.93M–

More Lakefront Biotherapeutics figures

See a number that looks wrong?